SEC Comment Letter 0000000000-23-012456 to ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC.
Date: Nov. 14, 2023 · CIK: 0001513525 · Accession: 0000000000-23-012456
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275397
Letter
United States securities and exchange commission logo November 14, 2023 Cary Claiborne President and Chief Executive Officer Adial Pharmaceuticals, Inc. 1180 Seminole Trail, Suite 495 Charlottesville, Virginia 22901 Re:Adial Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed November 8, 2023 File No. 333-275397 Dear Cary Claiborne: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Leslie Marlow
Show Raw Text
United States securities and exchange commission logo
November 14, 2023
Cary Claiborne
President and Chief Executive Officer
Adial Pharmaceuticals, Inc.
1180 Seminole Trail, Suite 495
Charlottesville, Virginia 22901
Re:Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed November 8, 2023
File No. 333-275397
Dear Cary Claiborne:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Leslie Marlow